Supplementary Figure S1 from Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression

September 2, 2025Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The findings suggest synergy between ATR inhibition and Lurbinectedin in treating soft-tissue sarcomas, enhancing therapeutic options.
Key evidence indicates that SLFN11 expression may serve as a biomarker for predicting sensitivity to Lurbinectedin in multiple cell lines.
This study uses a dose response analysis to evaluate the efficacy of Lurbinectedin across 14 different cell lines representing soft-tissue sarcomas.
The implications suggest a need for further exploration of SLFN11 expression as a predictive marker, influencing treatment approaches.

Answers are grounded in this paper and cite their sources.

Observational analysis reveals a predictive role of SLFN11 expression in response to Lurbinectedin treatment for soft-tissue sarcomas.

Fig 1 supplementary: Lurbinectedin dose response sigmoid curves for the 14 cell lines

No takes yet. Share an insight, caveat, or question.

Laroche‐Clary et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share